×


 x 

Shopping cart
Filip Mussen - Benefit-Risk Appraisal of Medicines - 9780470060858 - V9780470060858
Stock image for illustration purposes only - book cover, edition or condition may vary.

Benefit-Risk Appraisal of Medicines

€ 146.72
FREE Delivery in Ireland
Description for Benefit-Risk Appraisal of Medicines Hardcover. Establishes the criteria required to assess benefit-risk in general and reviews the current practice of benefit-risk assessment by drug regulatory authorities and the pharmaceutical industry. Outlines how the new MCDA model was developed and evaluated, and discusses the implications of its implementation into the practice of drug evaluation. Num Pages: 304 pages, Illustrations. BIC Classification: MBGR; MMG. Category: (P) Professional & Vocational. Dimension: 252 x 174 x 21. Weight in Grams: 670.
Benefit-risk assessment is at the centre of the approval process for every new medicine. The ability to assess the risks of a new medicine accurately and to balance these against the benefits the medicine could bring is critical for every regulatory authority and pharmaceutical company. Despite this there are very few tried and tested evaluative models currently available.

The authors of this book have developed a new, pioneering tool for the assessment of benefits and risks for new medicines in development. This model utilises a multi-criteria decision analysis which involves selecting, scoring and weighting key benefit and risk attributes ... Read more

Benefit-Risk Appraisal of Medicines establishes the background and criteria required to assess benefit and risk in general and reviews the current practices by regulatory authorities and the pharmaceutical industry, including those models currently available. It outlines the development and evaluation of the authors’ new model and analyses the implications of its implementation.

  • Describes an innovative, systematic model which leads to transparent and responsible benefit-risk decision making
  • Contributes important ideas to the debate on benefit-risk appraisal
  • Provides a future framework for benefit-risk appraisal of medicines

Benefit-Risk Appraisal of Medicines covers the entire process from the discovery of new medicines to their marketing and is ideal for all those who work in the pharmaceutical industry and regulatory authorities,, as well as post-graduate students of pharmaceutical medicine and clinical pharmacology.

Show Less

Product Details

Format
Hardback
Publication date
2010
Publisher
John Wiley and Sons Ltd United Kingdom
Number of pages
304
Condition
New
Number of Pages
304
Place of Publication
New York, United States
ISBN
9780470060858
SKU
V9780470060858
Shipping Time
Usually ships in 15 to 20 working days
Ref
99-15

About Filip Mussen
Dr Sam Salek, Reader in Pharmacoepidemiology, Director - WSP Centre for Socioeconomic Research; Director - Postgraduate Course in Pharmaceutical Medicine, Cardiff University, UK. Mr Filip Mussen, Johnson & Johnson Pharmaceuticals Research and Development, Belgium. Prof Stuart Walker, President and Founder, International Institute for Regulatory Science, UK.

Reviews for Benefit-Risk Appraisal of Medicines

Goodreads reviews for Benefit-Risk Appraisal of Medicines


Subscribe to our newsletter

News on special offers, signed editions & more!